The Europe Bovine Respiratory Disease Treatment Market was estimated at USD 11.06 million in 2023. This value is further projected to grow and worth USD 28.10 million by 2028, hiking at a CAGR of 20.5% during the forecast period.
There is a huge influence of bovine respiratory disease (BRD), diarrhea, arthritis, and otitis on the economically significant mortality parameters, hot carcass weight (HCW), carcass quality, fat cover, and meat color, which produces a problem for the cattle production.
BRD is a complex multifactorial disease that involves an interaction between several factors. In the current scenario, body temperature has been used to determine whether treatment should be done or not. Body temperature is such an important diagnostic test that many feedlots will treat animals based upon an undifferentiated fever.
A combination of disease organisms is usually accountable for respiratory infection and illness, but other factors also affect animals' health. Environmental factors, particularly transport, have been associated with BRD; the weather has always been implicated in the disease's occurrence. It has been concluded that stressful events, and others like calving or an overenthusiastic introduction to high grain rations, may precipitate BRD cases.
This research report segmented and sub-segmented the Europe Bovine Respiratory Disease Treatment Market into the following categories:
By Treatment Type:
Companies playing a notable role in the European Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale, and Vétoquinol S.A.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]